Business Effectiveness Cited As Key Component Of Compliance Programs
This article was originally published in The Gray Sheet
Executive Summary
Business considerations are as important as legal requirements for effective compliance programs, TAP Pharmaceutical Products VP and Ethics & Compliance Officer Stephan Vincze said Sept. 14 at a Food & Drug Law Institute meeting in Washington, D.C
You may also be interested in...
Medtronic whistleblowers
Firm receives copy of second civil qui tam complaint Sept. 2 on "allegations under the False Claims Act" similar to charges a September 2003 whistleblower brought against its Sofamor Danek spinal division, according to Medtronic's recent 110-Q filing. The Department of Justice is investigating "certain payments and other services provided to physicians by Medtronic" that may have been "improper inducements under the federal anti-kickback statute." The case is under seal at Memphis federal court. In its quarterly report filed with SEC Aug. 13, BD revealed it has been cited by a qui tam complaint, also on the False Claims Act (2"The Gray Sheet" Aug. 30, 2004, p. 22)...
Guidant Agrees With OIG To Educate Employees, Promote Reporting
Guidant will sidestep the more onerous requirements of its 1Corporate Integrity Agreement with HHS by dissolving its EVT division this fall
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.